Cargando…

External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy

Detection of residual oesophageal cancer after neoadjuvant chemoradiotherapy (nCRT) is important to guide treatment decisions regarding standard oesophagectomy or active surveillance. The aim was to validate previously developed (18)F-FDG PET-based radiomic models to detect residual local tumour and...

Descripción completa

Detalles Bibliográficos
Autores principales: Valkema, Maria J., Beukinga, Roelof J., Chatterjee, Avishek, Woodruff, Henry C., van Klaveren, David, Noordzij, Walter, Valkema, Roelf, Bennink, Roel J., Roef, Mark J., Schreurs, Wendy, Doukas, Michail, Lagarde, Sjoerd M., Wijnhoven, Bas P.L., Lambin, Philippe, Plukker, John T.M., van Lanschot, J. Jan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337315/
https://www.ncbi.nlm.nih.gov/pubmed/37132272
http://dx.doi.org/10.1097/MNM.0000000000001707
_version_ 1785071395186671616
author Valkema, Maria J.
Beukinga, Roelof J.
Chatterjee, Avishek
Woodruff, Henry C.
van Klaveren, David
Noordzij, Walter
Valkema, Roelf
Bennink, Roel J.
Roef, Mark J.
Schreurs, Wendy
Doukas, Michail
Lagarde, Sjoerd M.
Wijnhoven, Bas P.L.
Lambin, Philippe
Plukker, John T.M.
van Lanschot, J. Jan B.
author_facet Valkema, Maria J.
Beukinga, Roelof J.
Chatterjee, Avishek
Woodruff, Henry C.
van Klaveren, David
Noordzij, Walter
Valkema, Roelf
Bennink, Roel J.
Roef, Mark J.
Schreurs, Wendy
Doukas, Michail
Lagarde, Sjoerd M.
Wijnhoven, Bas P.L.
Lambin, Philippe
Plukker, John T.M.
van Lanschot, J. Jan B.
author_sort Valkema, Maria J.
collection PubMed
description Detection of residual oesophageal cancer after neoadjuvant chemoradiotherapy (nCRT) is important to guide treatment decisions regarding standard oesophagectomy or active surveillance. The aim was to validate previously developed (18)F-FDG PET-based radiomic models to detect residual local tumour and to repeat model development (i.e. ‘model extension’) in case of poor generalisability. METHODS: This was a retrospective cohort study in patients collected from a prospective multicentre study in four Dutch institutes. Patients underwent nCRT followed by oesophagectomy between 2013 and 2019. Outcome was tumour regression grade (TRG) 1 (0% tumour) versus TRG 2-3-4 (≥1% tumour). Scans were acquired according to standardised protocols. Discrimination and calibration were assessed for the published models with optimism-corrected AUCs >0.77. For model extension, the development and external validation cohorts were combined. RESULTS: Baseline characteristics of the 189 patients included [median age 66 years (interquartile range 60–71), 158/189 male (84%), 40/189 TRG 1 (21%) and 149/189 (79%) TRG 2-3-4] were comparable to the development cohort. The model including cT stage plus the feature ‘sum entropy’ had best discriminative performance in external validation (AUC 0.64, 95% confidence interval 0.55–0.73), with a calibration slope and intercept of 0.16 and 0.48 respectively. An extended bootstrapped LASSO model yielded an AUC of 0.65 for TRG 2-3-4 detection. CONCLUSION: The high predictive performance of the published radiomic models could not be replicated. The extended model had moderate discriminative ability. The investigated radiomic models appeared inaccurate to detect local residual oesophageal tumour and cannot be used as an adjunct tool for clinical decision-making in patients.
format Online
Article
Text
id pubmed-10337315
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-103373152023-07-13 External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy Valkema, Maria J. Beukinga, Roelof J. Chatterjee, Avishek Woodruff, Henry C. van Klaveren, David Noordzij, Walter Valkema, Roelf Bennink, Roel J. Roef, Mark J. Schreurs, Wendy Doukas, Michail Lagarde, Sjoerd M. Wijnhoven, Bas P.L. Lambin, Philippe Plukker, John T.M. van Lanschot, J. Jan B. Nucl Med Commun Original Articles Detection of residual oesophageal cancer after neoadjuvant chemoradiotherapy (nCRT) is important to guide treatment decisions regarding standard oesophagectomy or active surveillance. The aim was to validate previously developed (18)F-FDG PET-based radiomic models to detect residual local tumour and to repeat model development (i.e. ‘model extension’) in case of poor generalisability. METHODS: This was a retrospective cohort study in patients collected from a prospective multicentre study in four Dutch institutes. Patients underwent nCRT followed by oesophagectomy between 2013 and 2019. Outcome was tumour regression grade (TRG) 1 (0% tumour) versus TRG 2-3-4 (≥1% tumour). Scans were acquired according to standardised protocols. Discrimination and calibration were assessed for the published models with optimism-corrected AUCs >0.77. For model extension, the development and external validation cohorts were combined. RESULTS: Baseline characteristics of the 189 patients included [median age 66 years (interquartile range 60–71), 158/189 male (84%), 40/189 TRG 1 (21%) and 149/189 (79%) TRG 2-3-4] were comparable to the development cohort. The model including cT stage plus the feature ‘sum entropy’ had best discriminative performance in external validation (AUC 0.64, 95% confidence interval 0.55–0.73), with a calibration slope and intercept of 0.16 and 0.48 respectively. An extended bootstrapped LASSO model yielded an AUC of 0.65 for TRG 2-3-4 detection. CONCLUSION: The high predictive performance of the published radiomic models could not be replicated. The extended model had moderate discriminative ability. The investigated radiomic models appeared inaccurate to detect local residual oesophageal tumour and cannot be used as an adjunct tool for clinical decision-making in patients. Lippincott Williams & Wilkins 2023-08 2023-05-03 /pmc/articles/PMC10337315/ /pubmed/37132272 http://dx.doi.org/10.1097/MNM.0000000000001707 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Valkema, Maria J.
Beukinga, Roelof J.
Chatterjee, Avishek
Woodruff, Henry C.
van Klaveren, David
Noordzij, Walter
Valkema, Roelf
Bennink, Roel J.
Roef, Mark J.
Schreurs, Wendy
Doukas, Michail
Lagarde, Sjoerd M.
Wijnhoven, Bas P.L.
Lambin, Philippe
Plukker, John T.M.
van Lanschot, J. Jan B.
External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
title External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
title_full External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
title_fullStr External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
title_full_unstemmed External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
title_short External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
title_sort external validation of (18)f-fdg pet-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337315/
https://www.ncbi.nlm.nih.gov/pubmed/37132272
http://dx.doi.org/10.1097/MNM.0000000000001707
work_keys_str_mv AT valkemamariaj externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT beukingaroelofj externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT chatterjeeavishek externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT woodruffhenryc externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT vanklaverendavid externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT noordzijwalter externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT valkemaroelf externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT benninkroelj externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT roefmarkj externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT schreurswendy externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT doukasmichail externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT lagardesjoerdm externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT wijnhovenbaspl externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT lambinphilippe externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT plukkerjohntm externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy
AT vanlanschotjjanb externalvalidationof18ffdgpetbasedradiomicmodelsonidentificationofresidualoesophagealcancerafterneoadjuvantchemoradiotherapy